BioNTech and Duality Biologics reported success in a Phase 3 interim analysis for their HER2-targeting antibody-drug conjugate trastuzumab pamirtecan, demonstrating superior progression-free survival versus Roche’s Kadcyla in patients with HER2-positive unresectable or metastatic breast cancer who have received prior therapies. The China-based trial conducted by Duality could lead to marketing approval submissions with the NMPA, marking BioNTech’s first Phase 3 oncology triumph and potentially expanding treatment options for hard-to-treat breast cancer.